Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:982854.
doi: 10.4061/2011/982854. Epub 2011 Jun 27.

Calcific uremic arteriolopathy in peritoneal dialysis populations

Affiliations

Calcific uremic arteriolopathy in peritoneal dialysis populations

Nicholas New et al. Int J Nephrol. 2011.

Abstract

Calciphylaxis or calcific uremic arteriolopathy is an infrequent complication of end stage kidney disease. It is characterized by arteriolar medial calcification, thrombotic cutaneous ischemia, tissue necrosis often leading to ulceration, secondary infection and increased mortality rates. Current, multimodality treatment involves local wound care, well-controlled calcium, phosphate and parathyroid hormone levels and combination therapy with sodium thiosulfate and hyperbaric oxygen therapy. This combination therapy may be changing the historically poor prognosis of calcific uremic arteriolopathy reported in the literature. Peritoneal dialysis is considered a risk factor based on limited publications, however this remains to be proven. Clinical presentation, diagnosis, pathogenesis and treatment of calcific uremic arteriolopathy in these patients are no different from other patients manifesting with this condition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CUA lesion on the lateral abdominal wall with early ulceration, surrounding erythema and induration.
Figure 2
Figure 2
Large CUA lesion of the proximal lower limb with necrotic ulceration.
Figure 3
Figure 3
Characteristic biopsy specimen of CUA demonstrating circumferential calcification of small blood vessels with narrowing of the vascular lumen.
Figure 4
Figure 4
Schematic representation for the pathogenic mechanisms of CUA development and the potential sites of action for therapeutic intervention, where (+) indicates augmentation and (−) indicated inhibition; STS, sodium thiosulfate; HBO, hyperbaric oxygen; PO4, phosphate; Ca++, calcium; NDPT, sodium-dependent phosphate cotransporter (Pit-1); vSMC, vascular smooth muscle cell; Cbfa-1, core-binding factor alpha 1; NFκB, nuclear factor κ−B; RANK(L), receptor activator of NFκB (ligand); OPG, osteoprotegerin; TNF-α, tumour necrosis factor alpha; IL-1 interleukin 1; BMP, bone morphogenic protein; ESKD, end-stage kidney disease; MGP, matrix G1a protein; ASHG, α-2 Heremans-Schmid glycoprotein.

Similar articles

Cited by

References

    1. Bryant JH, White WH. A case of calcification of the arteries and obliterative endarterities associated with hydronephrosis in a child age six months. Guys Hospital Report. 1898;55: 1719
    1. Selye H. Calciphylaxis. Chicago, Ill, USA: University of Chicago Press; 1962.
    1. Rogers NM, Teubner DJO, Coates PTH. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Seminars in Dialysis. 2007;20(2):150–157. - PubMed
    1. Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. Journal of the American Academy of Dermatology. 2007;56(4):569–579. - PubMed
    1. Wilmer WA, Magro CM. Calciphylaxis: rmerging concepts in prevention, diagnosis, and treatment. Seminars in Dialysis. 2002;15(3):172–186. - PubMed

LinkOut - more resources